Skip to main content
Erschienen in:

01.12.2014 | Multiple Myeloma (R Niesvizky, Section Editor)

Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques

verfasst von: Noa Biran, Scott Ely, Ajai Chari

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Minimal residual disease (MRD) assessment has gained importance in the response evaluation of multiple myeloma. As discussed in part 1 of this two-part series, techniques such as multiparameter flow cytometry, polymerase chain reaction, and next-generation sequencing, of both bone marrow and peripheral blood, have the potential to achieve a high level of sensitivity, up to 1 in 10−6 cells, enabling analysis of genetically diverse subclones. Here, we review the clinical utility of MRD assessment using these techniques. Specifically, we review the association between MRD-negativity and progression-free or overall survival in various clinical settings (post-induction, post-auto or allo-stem cell transplant, transplant ineligible, maintenance, and relapsed/refractory). Currently, the goal of assessing MRD in multiple myeloma (MM) is to allow for a risk-stratified approach to therapy and for earlier identification of response to novel agents, particularly in the setting of clinical trials.
Literatur
1.
Zurück zum Zitat Cavo M et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol : Off J Am Soc Clin Oncol. 2007;25(17):2434–41.CrossRef Cavo M et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol : Off J Am Soc Clin Oncol. 2007;25(17):2434–41.CrossRef
2.
Zurück zum Zitat Alvares CL et al. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. Br J Haematol. 2005;129(5):607–14.PubMedCrossRef Alvares CL et al. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. Br J Haematol. 2005;129(5):607–14.PubMedCrossRef
3.
Zurück zum Zitat Barlogie B et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93(1):55–65.PubMed Barlogie B et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93(1):55–65.PubMed
4.
Zurück zum Zitat Child JA et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875–83.PubMedCrossRef Child JA et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875–83.PubMedCrossRef
5.
Zurück zum Zitat Richardson PG et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679–86.PubMedCentralPubMedCrossRef Richardson PG et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679–86.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Attal M et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–91.PubMedCrossRef Attal M et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–91.PubMedCrossRef
8.
Zurück zum Zitat Mateos MV et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11(10):934–41.PubMedCrossRef Mateos MV et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11(10):934–41.PubMedCrossRef
9.
Zurück zum Zitat Kumar S et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119(19):4375–82.PubMedCrossRef Kumar S et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119(19):4375–82.PubMedCrossRef
10.
Zurück zum Zitat Ladetto, M., et al., Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia, 2013 Ladetto, M., et al., Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia, 2013
11.
Zurück zum Zitat Cavo M et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood. 2000;96(1):355–7.PubMed Cavo M et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood. 2000;96(1):355–7.PubMed
12.
Zurück zum Zitat Corradini P et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood. 2003;102(5):1927–9.PubMedCrossRef Corradini P et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood. 2003;102(5):1927–9.PubMedCrossRef
13.
Zurück zum Zitat Fenk R et al. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma. Haematologica. 2004;89(5):557–66.PubMed Fenk R et al. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma. Haematologica. 2004;89(5):557–66.PubMed
14.
Zurück zum Zitat Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–54.PubMedCrossRef Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–54.PubMedCrossRef
15.
Zurück zum Zitat Klein B et al. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863–72.PubMed Klein B et al. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863–72.PubMed
16.
Zurück zum Zitat Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol : Off J Am Soc Clin Oncol. 2010;28(15):2612–24.CrossRef Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol : Off J Am Soc Clin Oncol. 2010;28(15):2612–24.CrossRef
17.
Zurück zum Zitat Hoering A et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood. 2009;114(7):1299–305.PubMedCentralPubMedCrossRef Hoering A et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood. 2009;114(7):1299–305.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Kim JS et al. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant. 2009;15(4):463–70.CrossRef Kim JS et al. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant. 2009;15(4):463–70.CrossRef
19.
Zurück zum Zitat Desikan R et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95(12):4008–10.PubMed Desikan R et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95(12):4008–10.PubMed
20.
Zurück zum Zitat Attal M et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome New England J Med. 1996;335(2):91–7.CrossRef Attal M et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome New England J Med. 1996;335(2):91–7.CrossRef
21.
Zurück zum Zitat Niesvizky R et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol. 2008;143(1):46–53.PubMedCrossRef Niesvizky R et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol. 2008;143(1):46–53.PubMedCrossRef
22.
Zurück zum Zitat Attal M et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495–502.PubMedCrossRef Attal M et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495–502.PubMedCrossRef
23.
Zurück zum Zitat van de Velde HJ et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92(10):1399–406.PubMedCrossRef van de Velde HJ et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92(10):1399–406.PubMedCrossRef
24.
Zurück zum Zitat Gay F et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117(11):3025–31.PubMedCrossRef Gay F et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117(11):3025–31.PubMedCrossRef
25.
Zurück zum Zitat Haessler J et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res : Off J Am Assoc Cancer Res. 2007;13(23):7073–9.CrossRef Haessler J et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res : Off J Am Assoc Cancer Res. 2007;13(23):7073–9.CrossRef
26.
Zurück zum Zitat Lachin JM. Statistical considerations in the intent-to-treat principle. Control Clin Trials. 2000;21(3):167–89.PubMedCrossRef Lachin JM. Statistical considerations in the intent-to-treat principle. Control Clin Trials. 2000;21(3):167–89.PubMedCrossRef
27.
Zurück zum Zitat Durie BG et al. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol : Off J Am Soc Clin Oncol. 2004;22(10):1857–63.CrossRef Durie BG et al. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol : Off J Am Soc Clin Oncol. 2004;22(10):1857–63.CrossRef
28.
Zurück zum Zitat Kapoor P et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(36):4529–35.CrossRef Kapoor P et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(36):4529–35.CrossRef
29.
Zurück zum Zitat Singhal S et al. The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood. 2009;114(1):38–9.PubMedCrossRef Singhal S et al. The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood. 2009;114(1):38–9.PubMedCrossRef
30.
Zurück zum Zitat Ludwig H et al. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia. 2013;27(1):213–9.PubMedCentralPubMedCrossRef Ludwig H et al. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia. 2013;27(1):213–9.PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Tovar N et al. Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation. Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant. 2012;18(7):1076–9.CrossRef Tovar N et al. Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation. Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant. 2012;18(7):1076–9.CrossRef
32.
Zurück zum Zitat Rawstron AC et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(20):2540–7.CrossRef Rawstron AC et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(20):2540–7.CrossRef
33.
Zurück zum Zitat Paiva B et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3):687–91.PubMedCrossRef Paiva B et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3):687–91.PubMedCrossRef
34.
Zurück zum Zitat Morgan GJ et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012;119(1):7–15.PubMedCrossRef Morgan GJ et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012;119(1):7–15.PubMedCrossRef
35.
Zurück zum Zitat Paiva B et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol : Off J Am Soc Clin Oncol. 2011;29(12):1627–33.CrossRef Paiva B et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol : Off J Am Soc Clin Oncol. 2011;29(12):1627–33.CrossRef
36.
Zurück zum Zitat Leung-Hagesteijn C et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24(3):289–304.PubMedCentralPubMedCrossRef Leung-Hagesteijn C et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24(3):289–304.PubMedCentralPubMedCrossRef
37.
Zurück zum Zitat Martinez-Lopez J et al. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results GEM/PETHEMA Stud British J Haematol. 2013;163(5):581–9.CrossRef Martinez-Lopez J et al. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results GEM/PETHEMA Stud British J Haematol. 2013;163(5):581–9.CrossRef
38.
Zurück zum Zitat Galimberti S et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res. 2005;29(8):961–6.PubMedCrossRef Galimberti S et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res. 2005;29(8):961–6.PubMedCrossRef
39.
Zurück zum Zitat Davies FE et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol. 2001;112(3):814–9.PubMedCrossRef Davies FE et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol. 2001;112(3):814–9.PubMedCrossRef
40.
Zurück zum Zitat Sarasquete ME et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90(10):1365–72.PubMed Sarasquete ME et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90(10):1365–72.PubMed
41.
Zurück zum Zitat Davies FE et al. Minimal residual disease monitoring in multiple myeloma. Best Pract Res Clin Haematol. 2002;15(1):197–222.PubMedCrossRef Davies FE et al. Minimal residual disease monitoring in multiple myeloma. Best Pract Res Clin Haematol. 2002;15(1):197–222.PubMedCrossRef
42.
Zurück zum Zitat Lioznov M et al. Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques. Bone Marrow Transplant. 2008;41(10):913–6.PubMedCrossRef Lioznov M et al. Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques. Bone Marrow Transplant. 2008;41(10):913–6.PubMedCrossRef
43.
Zurück zum Zitat Mason KD, Juneja S. Go with the flow for monitoring response in myeloma with minimal residual disease. Leuk Lymphoma. 2008;49(2):177–8.PubMedCrossRef Mason KD, Juneja S. Go with the flow for monitoring response in myeloma with minimal residual disease. Leuk Lymphoma. 2008;49(2):177–8.PubMedCrossRef
44.
Zurück zum Zitat Bakkus MH et al. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol. 2004;126(5):665–74.PubMedCrossRef Bakkus MH et al. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol. 2004;126(5):665–74.PubMedCrossRef
45.
Zurück zum Zitat Putkonen M et al. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. Eur J Haematol. 2010;85(5):416–23.PubMedCrossRef Putkonen M et al. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. Eur J Haematol. 2010;85(5):416–23.PubMedCrossRef
46.
Zurück zum Zitat Martinelli G et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol : Off J Am Soc Clin Oncol. 2000;18(11):2273–81. Martinelli G et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol : Off J Am Soc Clin Oncol. 2000;18(11):2273–81.
47.
Zurück zum Zitat Corradini P et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol : Off J Am Soc Clin Oncol. 1999;17(1):208–15. Corradini P et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol : Off J Am Soc Clin Oncol. 1999;17(1):208–15.
48.
Zurück zum Zitat Martinelli G et al. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica. 2000;85(9):930–4.PubMed Martinelli G et al. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica. 2000;85(9):930–4.PubMed
49.
Zurück zum Zitat Cremer FW et al. Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma. Bone Marrow Transplant. 2000;26(8):851–8.PubMedCrossRef Cremer FW et al. Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma. Bone Marrow Transplant. 2000;26(8):851–8.PubMedCrossRef
50.
Zurück zum Zitat Lemoli RM et al. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood. 2000;95(7):2234–9.PubMed Lemoli RM et al. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood. 2000;95(7):2234–9.PubMed
51.
Zurück zum Zitat Martinez-Lopez J et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073–9.PubMedCentralPubMedCrossRef Martinez-Lopez J et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073–9.PubMedCentralPubMedCrossRef
52.
Zurück zum Zitat Polzer B, Klein CA. Metastasis awakening: the challenges of targeting minimal residual cancer. Nat Med. 2013;19(3):274–5.PubMedCrossRef Polzer B, Klein CA. Metastasis awakening: the challenges of targeting minimal residual cancer. Nat Med. 2013;19(3):274–5.PubMedCrossRef
53.
54.
Zurück zum Zitat Bianchi G et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia. 2013;27(3):680–5.PubMedCentralPubMedCrossRef Bianchi G et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia. 2013;27(3):680–5.PubMedCentralPubMedCrossRef
55.
Zurück zum Zitat Kumar S et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol. 2005;23(24):5668–74.PubMedCrossRef Kumar S et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol. 2005;23(24):5668–74.PubMedCrossRef
56.
Zurück zum Zitat Nowakowski GS et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005;106(7):2276–9.PubMedCentralPubMedCrossRef Nowakowski GS et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005;106(7):2276–9.PubMedCentralPubMedCrossRef
57.
Zurück zum Zitat Peceliunas V et al. Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma. Leuk Lymphoma. 2012;53(4):641–7.PubMedCrossRef Peceliunas V et al. Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma. Leuk Lymphoma. 2012;53(4):641–7.PubMedCrossRef
58.
Zurück zum Zitat Paiva B et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood. 2013;122(22):3591–8.PubMedCrossRef Paiva B et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood. 2013;122(22):3591–8.PubMedCrossRef
59.
Zurück zum Zitat Vij R et al. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2014;14(2):131–139 e1.PubMedCrossRef Vij R et al. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2014;14(2):131–139 e1.PubMedCrossRef
60.
Zurück zum Zitat Bartel TB et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068–76.PubMedCentralPubMedCrossRef Bartel TB et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068–76.PubMedCentralPubMedCrossRef
61.
Zurück zum Zitat Zamagni E et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989–95.PubMedCrossRef Zamagni E et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989–95.PubMedCrossRef
62.
Zurück zum Zitat Walker R et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol : Off J Am Soc Clin Oncol. 2007;25(9):1121–8.CrossRef Walker R et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol : Off J Am Soc Clin Oncol. 2007;25(9):1121–8.CrossRef
63.
Zurück zum Zitat Waheed S et al. Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica. 2013;98(1):71–8.PubMedCentralPubMedCrossRef Waheed S et al. Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica. 2013;98(1):71–8.PubMedCentralPubMedCrossRef
64.
Zurück zum Zitat Cooke F et al. Use of quantitative ASO-PCR to predict relapse in multiple myeloma. Br J Haematol. 1999;105(1):317–9.PubMedCrossRef Cooke F et al. Use of quantitative ASO-PCR to predict relapse in multiple myeloma. Br J Haematol. 1999;105(1):317–9.PubMedCrossRef
65.
Zurück zum Zitat Ding C, Cantor CR. A high-throughput gene expression analysis technique using competitive PCR and matrix-assisted laser desorption ionization time-of-flight MS. Proc Natl Acad Sci U S A. 2003;100(6):3059–64.PubMedCentralPubMedCrossRef Ding C, Cantor CR. A high-throughput gene expression analysis technique using competitive PCR and matrix-assisted laser desorption ionization time-of-flight MS. Proc Natl Acad Sci U S A. 2003;100(6):3059–64.PubMedCentralPubMedCrossRef
67.
Zurück zum Zitat Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol/Oncol Clin North Am. 1999;13(6):1259–72.CrossRef Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol/Oncol Clin North Am. 1999;13(6):1259–72.CrossRef
68.
Zurück zum Zitat Snozek CL et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. 2008;22(10):1933–7.PubMedCentralPubMedCrossRef Snozek CL et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. 2008;22(10):1933–7.PubMedCentralPubMedCrossRef
70.
Zurück zum Zitat Novella E et al. Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma. Haematologica. 2002;87(11):1157–64.PubMed Novella E et al. Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma. Haematologica. 2002;87(11):1157–64.PubMed
71.
Zurück zum Zitat Puig N et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. Comp Anal Flow Cytometry Leuk. 2014;28(2):391–7. Puig N et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. Comp Anal Flow Cytometry Leuk. 2014;28(2):391–7.
72.
Zurück zum Zitat Walker RC et al. Imaging of multiple myeloma and related plasma cell dyscrasias. J Nucl Med. 2012;53(7):1091–101.PubMedCrossRef Walker RC et al. Imaging of multiple myeloma and related plasma cell dyscrasias. J Nucl Med. 2012;53(7):1091–101.PubMedCrossRef
Metadaten
Titel
Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques
verfasst von
Noa Biran
Scott Ely
Ajai Chari
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 4/2014
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-014-0237-y

Neu im Fachgebiet Onkologie

Körperlich fitte Krebskranke leben länger

Krebspatienten, auch und vor allem solche in fortgeschrittenen Stadien, profitieren offenbar von guter körperlicher Verfassung. Hohe Muskelkraft und kardiorespiratorische Fitness sind laut Ergebnissen einer Metaanalyse mit geringerer Mortalität assoziiert.

Kein (großer) Schutz vor Kolorektalkarzinom-Rezidiven durch ASS

Die erste Phase-3-Studie zum Nutzen von ASS in der adjuvanten Therapie des kolorektalen Karzinoms ist negativ verlaufen. Das abschließende Urteil über eine Sekundärprävention mit ASS ist trotzdem noch nicht gefallen.

Frühe CLL-Therapie: BTK-Hemmer verlängert EFS und PFS, aber nicht OS

Auch nach sechs Jahren ergibt sich kein Überlebensvorteil einer Therapie mit dem BTK-Hemmer Ibrutinib für Menschen mit frühem CLL-Stadium und erhöhtem Progressionsrisiko. Die Progressionsrate wird mit der Behandlung jedoch um über 80% gesenkt.

Adjuvantes Atezolizumab ohne Nutzen bei frühem TNBC

Patientinnen mit frühem triple-negativem Brustkrebs profitieren nach der Operation offenbar nicht von einer Zugabe des PD-L1-Hemmers Atezolizumab zur adjuvanten Standardchemotherapie. Die Studie, die das untersucht hat, wurde vorzeitig abgebrochen. Was könnte die schlechte Wirksamkeit erklären?

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.